VANCOUVER, Washington, November 24, 2025 — Leads & Copy — CytoDyn Inc. announced that Dr. Milana V. Dolezal, Clinical Associate Professor, Medicine Oncology at Stanford University School of Medicine, will present a poster at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.
The poster presentation will feature clinical data demonstrating sustained remission following immune checkpoint inhibitor (ICI) therapy with or after leronlimab treatment in patients with metastatic or locally advanced triple-negative breast cancer (mTNBC).
According to CytoDyn, mTNBC is associated with a poor prognosis, and the efficacy of ICIs is reduced in patients with low levels of PD-L1.
CytoDyn’s prior oncology trials suggest treatment with leronlimab was associated with an increase in PD-L1 levels, and when combined with or preceded by an ICI, it may improve survival in patients with mTNBC.
“Our strategy to use leronlimab in a combined approach with ICIs continues to demonstrate great promise,” said Jacob Lalezari, M.D., CEO of CytoDyn.
At SABCS 2025, CytoDyn will share details on mTNBC patients treated with leronlimab and commercially available PD-L1/PD-1 immune checkpoint inhibitors who continue to demonstrate sustained long-term remission, including three individuals with no current evidence of disease, according to Lalezari.
The poster presentation details are:
Title: Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab-induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer
Presenter: Dr. Milana V. Dolezal, MD, MSci, Clinical Associate Professor, Medicine Oncology at Stanford University School of Medicine
Poster ID: PS5-02-30
Date/Time: December 12, 2025, 12:30 PM–2:00 PM CST
Location: Exhibit Hall
CytoDyn is a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including mTNBC and colorectal cancer.
CytoDyn is committed to improving patients’ quality of life through therapeutic innovation with integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.
A copy of the presentation will be available on CytoDyn’s website under the Publications & Posters section after the symposium.
Rob Haney, Ph.D., or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com
Source: CytoDyn Inc.
